Marileila Varella-Garcia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marileila Varella-Garcia has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Fred R. Hirsch
Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado
3 shared publicationsWilbur A. Franklin
Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado
3 shared publicationsHolly J. Wolf
Department of Preventive Medicine and Biostatistics, University of Colorado Health Sciences Center, Denver, Colorado
2 shared publications- Paul A. Bunn
University of Colorado Cancer Center, Aurora, CO
2 shared publications Robert L. Keith
Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado
2 shared publicationsTim Byers
Department of Preventive Medicine and Biostatistics, University of Colorado Health Sciences Center, Denver, Colorado
2 shared publications
Latest Publications
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 11030
Multi-institutional multiplexed genetic analysis in lung adenocarcinoma (AC): The Lung Cancer Mutation Consortium (LCMC I) experience.
11030 Background: Molecular analysis of lung AC has become standard of care for therapy selection. LCMC I collectively enrolled 1102 patients from 14 institutions with the goal of performing molecular analysis to identify therapy options. Technical aspects of the genomic testing, specimen and clinical correlations are presented. Methods: Testing for mutations in 8 genes (EGFR, KRAS, ERBB2, AKT1, BRAF, MEK1, NRAS, PIK3CA), and analysis of ALK and MET by FISH, was performed at 6 labs. Proficiency testing was carried out with blinded samples. Statistical analyses were performed for analysis completion, specimen types, testing methodology, mutation findings and clinical variables. Results: Five methodologies (SNaPshot®, mass spectrometry, Sanger +/- PNA, sizing) were variably employed for detection of mutations, with analytic sensitivities of ~5% allele frequency. All sites passed proficiency testing. 1006 specimens had at least one mutation analysis completed, 733 specimens had full genotyping results. Mutation detection rates did not vary according to method of analysis. Higher rates of specimen inadequacy were seen in biopsy (36/136; 23%) and cytology (23/65; 36%) compared to surgical (13/268; 5%) specimens at the site that analyzed the most cases. Biopsy and cytology samples, when acceptable showed no difference in mutation or FISH assay completion or positivity rate. Multiple analyses are summarized in the table. Double mutations were seen in 3.8% of samples. Conclusions: Molecular analysis is possible in a multi-institutional setting with consistent results. Cytology and small biopsy specimens were commonly sufficient for multiplex testing, although sample insufficiency was a common reason for exclusion (53% of excluded cases), and contributed to lack of assay completion. Multiple associations were identified between specific mutations and clinicopathologic features.
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 11030
Multi-institutional multiplexed genetic analysis in lung adenocarcinoma (AC): The Lung Cancer Mutation Consortium (LCMC I) experience.
11030 Background: Molecular analysis of lung AC has become standard of care for therapy selection. LCMC I collectively enrolled 1102 patients from 14 institutions with the goal of performing molecular analysis to identify therapy options. Technical aspects of the genomic testing, specimen and clinical correlations are presented. Methods: Testing for mutations in 8 genes (EGFR, KRAS, ERBB2, AKT1, BRAF, MEK1, NRAS, PIK3CA), and analysis of ALK and MET by FISH, was performed at 6 labs. Proficiency testing was carried out with blinded samples. Statistical analyses were performed for analysis completion, specimen types, testing methodology, mutation findings and clinical variables. Results: Five methodologies (SNaPshot®, mass spectrometry, Sanger +/- PNA, sizing) were variably employed for detection of mutations, with analytic sensitivities of ~5% allele frequency. All sites passed proficiency testing. 1006 specimens had at least one mutation analysis completed, 733 specimens had full genotyping results. Mutation detection rates did not vary according to method of analysis. Higher rates of specimen inadequacy were seen in biopsy (36/136; 23%) and cytology (23/65; 36%) compared to surgical (13/268; 5%) specimens at the site that analyzed the most cases. Biopsy and cytology samples, when acceptable showed no difference in mutation or FISH assay completion or positivity rate. Multiple analyses are summarized in the table. Double mutations were seen in 3.8% of samples. Conclusions: Molecular analysis is possible in a multi-institutional setting with consistent results. Cytology and small biopsy specimens were commonly sufficient for multiplex testing, although sample insufficiency was a common reason for exclusion (53% of excluded cases), and contributed to lack of assay completion. Multiple associations were identified between specific mutations and clinicopathologic features.
- 1 February 2008
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 177 (3) , 342-347
Chromosomal Aneusomy in Bronchial High-Grade Lesions Is Associated with Invasive Lung Cancer
Rationale: The development of lung cancer (LC) is accompanied by field changes in the airway mucosa that may have prognostic importance. Objectives: To compare patients with prevalent LC to control subjects regarding their histologic dysplasia scores and chromosomal aneusomy as measured by fluorescence in situ hybridization (FISH). Methods: The most advanced bronchial histology lesion was assessed from each of 44 LC cases and 90 cancer-free control subjects using a four-color FISH probe set encompassing the chromosome 6 centromere, 5p15.2, 7p12 (epidermal growth factor receptor), and 8q24 v-myc myelocytomatosis viral oncogene homolog (MYC) sequences. Histology grades were coded as dysplasia (moderate or severe) or carcinoma in situ (CIS). Measurements and Main Results: CIS was the highest histologic grade for 32 subjects, and dysplasia was the highest grade for 102 subjects (54 moderate, 48 severe). Chromosomal aneusomy was seen in 64% of the LC cases, but in only 31% of the control subjects (odds ratio [OR], 4.68; 95% confidence interval [CI]. 1.97–11.04). Among those with any level of dysplasia, the OR for positive FISH and LC was 2.28 (95% CI, 0.75–6.86). Among those with CIS, the OR for positive FISH and LC was 5.84 (95% CI, 1.31–26.01). Conclusions: Chromosomal aneusomy is associated with LC. Prospective examination of aneusomy as a precursor lesion that predicts LC is needed.
- 1 February 2008
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 177 (3) , 342-347
Chromosomal Aneusomy in Bronchial High-Grade Lesions Is Associated with Invasive Lung Cancer
Rationale: The development of lung cancer (LC) is accompanied by field changes in the airway mucosa that may have prognostic importance. Objectives: To compare patients with prevalent LC to control subjects regarding their histologic dysplasia scores and chromosomal aneusomy as measured by fluorescence in situ hybridization (FISH). Methods: The most advanced bronchial histology lesion was assessed from each of 44 LC cases and 90 cancer-free control subjects using a four-color FISH probe set encompassing the chromosome 6 centromere, 5p15.2, 7p12 (epidermal growth factor receptor), and 8q24 v-myc myelocytomatosis viral oncogene homolog (MYC) sequences. Histology grades were coded as dysplasia (moderate or severe) or carcinoma in situ (CIS). Measurements and Main Results: CIS was the highest histologic grade for 32 subjects, and dysplasia was the highest grade for 102 subjects (54 moderate, 48 severe). Chromosomal aneusomy was seen in 64% of the LC cases, but in only 31% of the control subjects (odds ratio [OR], 4.68; 95% confidence interval [CI]. 1.97–11.04). Among those with any level of dysplasia, the OR for positive FISH and LC was 2.28 (95% CI, 0.75–6.86). Among those with CIS, the OR for positive FISH and LC was 5.84 (95% CI, 1.31–26.01). Conclusions: Chromosomal aneusomy is associated with LC. Prospective examination of aneusomy as a precursor lesion that predicts LC is needed.
- Open Access
- 1 August 2007
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (8) , S322
A5-01: Epidermal growth factor receptor (EGFR) gene amplification in non-small cell lung cancer (NSCLC): molecular patterns and sensitivity to tyrosine kinase inhibitors
- 1 August 2007
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (8) , S322
Open AccessA5-01: Epidermal growth factor receptor (EGFR) gene amplification in non-small cell lung cancer (NSCLC): molecular patterns and sensitivity to tyrosine kinase inhibitors
- Open Access
- 1 January 2006
- Published by Springer Nature in Diagnostic Pathology
- Vol. 1 (1) , 19
Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay
DNA fluorescence in situ hybridization (FISH) technology is used to study chromosomal and genomic changes in fixed cell suspensions and tissue block preparations. The technique is based on specific hybridization of small labeled DNA fragments, the probes, to complementary sequences in a target DNA molecule. Demand for FISH assays in formalin-fixed, paraffin-embedded tissues has been increasing, mainly in conditions in which diagnosis is not achieved in cell smears or tissue imprints, such as solid tumors. Moreover, the development of molecular targeted therapies in oncology has expanded the applicability of tests to predict sensitivity or resistance to these agents. The efficient use of tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) as therapeutical agents in advanced non-small cell lung cancer (NSCLC) depends on identification of patients likely to show clinical benefit from these specific treatments. The EGFR gene copy number determined by FISH has been demonstrated as an effective predictor of outcome from NSCLC patients to EGFR TKIs; however there are pending challenges for standardization of laboratory procedures and definition of the scoring system. This methodology article focuses on the EGFR FISH assay. It details the scoring system used in the studies conducted at the University of Colorado Cancer Center in which a significant association was found between increased EGFR copy numbers and clinical outcome to TKIs, and proposes interpretative guidelines for molecular stratification of NSCLC patients for TKI therapy.
- 1 January 2006
- Published by Springer Nature in Diagnostic Pathology
- Vol. 1 (1) , 19
Open AccessStratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay
DNA fluorescence in situ hybridization (FISH) technology is used to study chromosomal and genomic changes in fixed cell suspensions and tissue block preparations. The technique is based on specific hybridization of small labeled DNA fragments, the probes, to complementary sequences in a target DNA molecule. Demand for FISH assays in formalin-fixed, paraffin-embedded tissues has been increasing, mainly in conditions in which diagnosis is not achieved in cell smears or tissue imprints, such as solid tumors. Moreover, the development of molecular targeted therapies in oncology has expanded the applicability of tests to predict sensitivity or resistance to these agents. The efficient use of tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) as therapeutical agents in advanced non-small cell lung cancer (NSCLC) depends on identification of patients likely to show clinical benefit from these specific treatments. The EGFR gene copy number determined by FISH has been demonstrated as an effective predictor of outcome from NSCLC patients to EGFR TKIs; however there are pending challenges for standardization of laboratory procedures and definition of the scoring system. This methodology article focuses on the EGFR FISH assay. It details the scoring system used in the studies conducted at the University of Colorado Cancer Center in which a significant association was found between increased EGFR copy numbers and clinical outcome to TKIs, and proposes interpretative guidelines for molecular stratification of NSCLC patients for TKI therapy.
- Open Access
- 15 November 2005
- Published by Springer Nature in British Journal of Cancer
- Vol. 93 (12) , 1334-1340
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
In non-small-cell lung cancer (NSCLC), sensitivity to tyrosine kinase inhibitors (TKIs) is associated with activating mutations and genomic gain of the epidermal growth factor receptor (EGFR). Preclinical data suggested that HER3 overexpression increases sensitivity to TKIs. A total of 82 NSCLC patients treated with gefitinib (250 mg), and previously evaluated for EGFR and HER2 status by fluorescence in situ hybridisation (FISH) and DNA sequencing, and for Phospho-Akt status by immunohistochemistry, were investigated for HER3 genomic gain by FISH. Patients with high polysomy and gene amplification were considered as HER3 FISH positive (+). HER3 FISH+ pattern was significantly associated with female gender (P=0.02) and never smoking history (P=0.02). Patients with HER3+ tumours (26.8%) had a significantly longer time to progression (3.7 vs 2.7, P=0.04) than patients with HER3− tumours, but not a significantly better response rate or survival. Patients with EGFR+/HER3+ tumours had higher objective response rate (36.4 vs 9.9%, P=0.03) and time to progression (7.7 vs 2.7 months, P=0.03) than patients with EGFR− and/or HER3− tumours, but no significantly longer survival. No difference in response was observed according to HER3 status in patients with EGFR+ tumours. Patients with HER2+/HER3+ tumours had similar outcome as patients with HER2− and/or HER3− tumours. Significantly different clinical end points were not observed between patients with HER3+/P-Akt+ and HER3− and/or P-Akt− tumours. Genomic gain for HER3 is not a marker for response or resistance to TKI therapy in advanced NSCLC patients.
- 15 November 2005
- Published by Springer Nature in British Journal of Cancer
- Vol. 93 (12) , 1334-1340
Open AccessHER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
In non-small-cell lung cancer (NSCLC), sensitivity to tyrosine kinase inhibitors (TKIs) is associated with activating mutations and genomic gain of the epidermal growth factor receptor (EGFR). Preclinical data suggested that HER3 overexpression increases sensitivity to TKIs. A total of 82 NSCLC patients treated with gefitinib (250 mg), and previously evaluated for EGFR and HER2 status by fluorescence in situ hybridisation (FISH) and DNA sequencing, and for Phospho-Akt status by immunohistochemistry, were investigated for HER3 genomic gain by FISH. Patients with high polysomy and gene amplification were considered as HER3 FISH positive (+). HER3 FISH+ pattern was significantly associated with female gender (P=0.02) and never smoking history (P=0.02). Patients with HER3+ tumours (26.8%) had a significantly longer time to progression (3.7 vs 2.7, P=0.04) than patients with HER3− tumours, but not a significantly better response rate or survival. Patients with EGFR+/HER3+ tumours had higher objective response rate (36.4 vs 9.9%, P=0.03) and time to progression (7.7 vs 2.7 months, P=0.03) than patients with EGFR− and/or HER3− tumours, but no significantly longer survival. No difference in response was observed according to HER3 status in patients with EGFR+ tumours. Patients with HER2+/HER3+ tumours had similar outcome as patients with HER2− and/or HER3− tumours. Significantly different clinical end points were not observed between patients with HER3+/P-Akt+ and HER3− and/or P-Akt− tumours. Genomic gain for HER3 is not a marker for response or resistance to TKI therapy in advanced NSCLC patients.
- 31 December 2004
- Published by Elsevier in Cancer Detection Prevention
- Vol. 28 (4) , 244-251
Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer
- 31 December 2004
- Published by Elsevier in Cancer Detection Prevention
- Vol. 28 (4) , 244-251
Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer
- 24 September 2003
- Published by Wiley in The Prostate
- Vol. 57 (3) , 226-244
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines
BACKGROUND Well-characterized in vitro model systems provide an invaluable tool for studying prostate cancer in the laboratory. Detailed karyotypes have been reported using modern techniques such as multiplex fluorescence in situ hybridization (M-FISH) and spectral karyotyping (SKY) for LNCaP, DU 145, NCI-H660, and PC-3 cell lines. However, karyotypic data for more recently established prostate carcinoma cell lines are still limited. METHODS Classical (G-banding) and SKY analyses were performed on ten prostate carcinoma cell lines: 22Rv1, CWR-R1, DuCaP, LAPC-4, MDA PCa 1, MDA PCa 2a, MDA PCa 2b, PC-346C, PSK-1, and VCaP. RESULTS Chromosomal abnormalities were identified in all cell lines, although the number and complexity varied greatly among them. PC-346C, established from a primary tumor, exhibited the lowest number (3) of clonal structural abnormalities, while DuCaP, established from a metastasis from a hormone-refractory patient, exhibited both the highest number (31) and largest complexity of structural abnormalities. In various subsets of these models, breakpoints were identified in chromosomal regions previously described as being involved in prostate cancer (e.g., 8p, 10q, 13q, and 16q). CONCLUSIONS The present study provides a comprehensive karyotypic analysis of a large number of prostate carcinoma cell lines, and offers a valuable resource for future investigations. Prostate 57: 226–244, 2003.
- 24 September 2003
- Published by Wiley in The Prostate
- Vol. 57 (3) , 226-244
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines
BACKGROUND Well-characterized in vitro model systems provide an invaluable tool for studying prostate cancer in the laboratory. Detailed karyotypes have been reported using modern techniques such as multiplex fluorescence in situ hybridization (M-FISH) and spectral karyotyping (SKY) for LNCaP, DU 145, NCI-H660, and PC-3 cell lines. However, karyotypic data for more recently established prostate carcinoma cell lines are still limited. METHODS Classical (G-banding) and SKY analyses were performed on ten prostate carcinoma cell lines: 22Rv1, CWR-R1, DuCaP, LAPC-4, MDA PCa 1, MDA PCa 2a, MDA PCa 2b, PC-346C, PSK-1, and VCaP. RESULTS Chromosomal abnormalities were identified in all cell lines, although the number and complexity varied greatly among them. PC-346C, established from a primary tumor, exhibited the lowest number (3) of clonal structural abnormalities, while DuCaP, established from a metastasis from a hormone-refractory patient, exhibited both the highest number (31) and largest complexity of structural abnormalities. In various subsets of these models, breakpoints were identified in chromosomal regions previously described as being involved in prostate cancer (e.g., 8p, 10q, 13q, and 16q). CONCLUSIONS The present study provides a comprehensive karyotypic analysis of a large number of prostate carcinoma cell lines, and offers a valuable resource for future investigations. Prostate 57: 226–244, 2003.
- 1 February 2003
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 8 (1) , 45-58
Molecular Cytogenetics in Solid Tumors: Laboratorial Tool for Diagnosis, Prognosis, and Therapy
Learning Objectives: After completing this course, the reader will be able to: Explain the basic principles supporting the FISH technology and list examples of methodology variants suitable for analysis in metaphase and interphase cells. Describe at least one advantageous and one limiting factor for the expansion of the applicability of FISH assays to solid tumors. Explain technical strategies for detection of chromosomal translocation in nondividing cells. Illustrate applications of cytogenetic markers to solid malignancies for diagnosis, prognosis, selection of therapy, and monitoring disease recurrence or response to treatment. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com The remarkable progress in the understanding of leukemogenesis was soundly sustained by methodological developments in the cytogenetic field. Nonrandom chromosomal abnormalities frequently associated with specific types of hematological disease play a major role in their diagnosis and have been demonstrated as independent prognostic indicators. Molecular pathways altered by chimeric or deregulated proteins as a consequence of chromosomal abnormalities have also significantly contributed to the development of targeted therapies, and cytogenetic assays are valuable for selecting patients for treatment and monitoring outcome. In solid tumors, significantly high levels of chromosome abnormalities have been detected, but distinction between critical and irrelevant events has been a major challenge. Consequently, the application of cytogenetic technology as diagnostic, prognostic, or therapeutic tools for these malignancies remains largely underappreciated. The emergence of molecular-based techniques such as fluorescence in situ hybridization was particularly useful for solid malignancies, and the spectrum of their application is rapidly expanding to improve efficiency and sensitivity in cancer prevention, diagnosis, prognosis, and therapy selection, alone or in combination with other diagnostic methods. This overview illustrates current uses and outlines potential applications for molecular cytogenetics in clinical oncology.
- 1 February 2003
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 8 (1) , 45-58
Molecular Cytogenetics in Solid Tumors: Laboratorial Tool for Diagnosis, Prognosis, and Therapy
Learning Objectives: After completing this course, the reader will be able to: Explain the basic principles supporting the FISH technology and list examples of methodology variants suitable for analysis in metaphase and interphase cells. Describe at least one advantageous and one limiting factor for the expansion of the applicability of FISH assays to solid tumors. Explain technical strategies for detection of chromosomal translocation in nondividing cells. Illustrate applications of cytogenetic markers to solid malignancies for diagnosis, prognosis, selection of therapy, and monitoring disease recurrence or response to treatment. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com The remarkable progress in the understanding of leukemogenesis was soundly sustained by methodological developments in the cytogenetic field. Nonrandom chromosomal abnormalities frequently associated with specific types of hematological disease play a major role in their diagnosis and have been demonstrated as independent prognostic indicators. Molecular pathways altered by chimeric or deregulated proteins as a consequence of chromosomal abnormalities have also significantly contributed to the development of targeted therapies, and cytogenetic assays are valuable for selecting patients for treatment and monitoring outcome. In solid tumors, significantly high levels of chromosome abnormalities have been detected, but distinction between critical and irrelevant events has been a major challenge. Consequently, the application of cytogenetic technology as diagnostic, prognostic, or therapeutic tools for these malignancies remains largely underappreciated. The emergence of molecular-based techniques such as fluorescence in situ hybridization was particularly useful for solid malignancies, and the spectrum of their application is rapidly expanding to improve efficiency and sensitivity in cancer prevention, diagnosis, prognosis, and therapy selection, alone or in combination with other diagnostic methods. This overview illustrates current uses and outlines potential applications for molecular cytogenetics in clinical oncology.